Drug Type Small molecule drug |
Synonyms Phenytoin sodium (USP), Phenytoin sodium for injection (JP17), Aurantin + [6] |
Target |
Mechanism SCNA blockers(Sodium channel alpha subunit blockers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (01 Mar 1956), |
Regulation- |
Molecular FormulaC15H12N2O2 |
InChIKeyCXOFVDLJLONNDW-UHFFFAOYSA-N |
CAS Registry57-41-0 |
Start Date28 Jul 2021 |
Sponsor / Collaborator |
Start Date01 Mar 2021 |
Sponsor / Collaborator |
Start Date04 Dec 2018 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02103 | Phenytoin sodium | - |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Not Applicable | 160 | tilwkfrobc(mbsmaicwqy) = mzzsfzcxsb iqyjnuvnhw (bvuvhiyqdi, -3.08) | - | 01 Sep 2015 | |||
tilwkfrobc(mbsmaicwqy) = kkmkqgvmyg iqyjnuvnhw (bvuvhiyqdi, -3.05) | |||||||
Phase 2 | Secondary malignant neoplasm of pancreas Second line | 49 | SirolimusSirolimus/Phenytoin/Methoxsalen/Tyrosine isomerMethoxsalen/Tyrosine isomer+Methoxsalen+Phenytoin sodium+Sirolimus | (zzsogthahs) = efzcwarcby etezkuelju (ubmzblxphb ) View more | Positive | 02 May 2022 |